Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Regeneron receives another CRL for its Eyelea 8 mg | Ophthalmology Times
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the company’s request for approval of its prefilled syringe option of high-dose (HD) Eylea (aflibercept) 8 mg.1 The FDA cited unresolved…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…
Throwback Series: Managing childhood glaucoma in a resource-limited locale | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed today.…
Research supports that iron dysregulation may drive AMD | Ophthalmology Times
Image credit: AdobeStock/Gorodenkoff A new study supports the hypothesis that iron dysregulation may be a driver of dry age-related macular degeneration (AMD). This could be especially true in the early stage of geographic atrophy (GA). According to the research, the…
Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months | Ophthalmology Times
Image credit: AdobeStock/oz Interim 24-month data from a trial of the bimatoprost drug pad-IOL system (BIM-IOL system) showed sustained improvements in intraocular pressure (IOP) and visual acuity outcomes.1 The BIM-IOL system has been developed by SpyGlass Pharma, Inc. The company…
Q&A: William F. Wiley, MD, on what BVI’s trifocal IOL approval means for US premium vision options | Ophthalmology Times
The FDA’s approval of the FineVision HP trifocal lens expands the range of premium lens option to US ophthalmologists and their patients. (Image credit: AdobeStock/Margarita Ratatosk) As the landscape of ophthalmic innovation continues to evolve, new technologies are reshaping how…
ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times
Image credit: AdobeStock/zimmytws The annual scientific meeting of the American Academy of Ophthalmology (AAO) was held in Orlando, Florida. At this meeting, presenters and companies highlighted new technologies and continued areas of research. Ophthalmology Times is highlighting some stories that…
Evolving glaucoma therapy: A new era of interventional strategies | Ophthalmology Times
(Image Credit: AdobeStock/Yakobchuk Olena) Inder Paul Singh, MD, from The Eye Centers of Racine and Kenosha, Wisconsin, recently moderated an Ophthalmology Times Case-Based Roundtable that addressed the new playing field in glaucoma care. For Singh, the term interventional glaucoma no…
Development of maculopathy associated with systemic medications | Ophthalmology Times
Image credit: AdobeStock/James Thew A new study conducted by researchers at Hanyang University, Seoul, Republic of Korea, and the University of North Carolina, Chapel Hill, identified 5 systemic drugs that cause maculopathy that had previously been under-recognized. The researchers, led…